Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer.
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Videos — February 6, 2024
Chief, Division of Breast Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA
Associate Professor of Medicine, Harvard Medical School
Boston, MA
